This U-PGx video visualises and promotes the idea of personalised medicine and pre-emptive PGx testing. The video can be be used to inform the public via the webpage, for educational purpose and for communication with stakeholders and at (inter)national workshops. Continue reading
The study reported by Kapoor et al in this month’s European Journal of Human Genetics explains the dichotomy between the accelerated pace of discovery and the slow uptake of pharmacogenomics in standard clinical care through a SWOT analysis. A glass can be perceived as being half-full or half-empty. Continue reading
David Haerry is a patients’ advocate. He is a member of the European AIDS Treatment Group (EATG). David has been involved in HIV drug development for many years and has specific interests in the areas of Personalised Medicine, Risk Communication and Doctor/Patient Communication, Pharmacovigilance, Observational Studies, Biomedical Prevention and HIV Eradication Research.
The 17th Golden Helix Pharmacogenomics Day was successfully organized in Rotterdam, the Netherlands May 27th, 2016 by the Golden Helix Foundation and the Erasmus University Medical Center. Overall, the conference was attended by 164 participants from over 10 countries from Europe and the United States and was under the auspices of several national and international organizations, such as the Dutch Royal Pharmacists Association, the Genomic Medicine Alliance, the International Federation of Clinical Chemistry, and others.
We are excited to report that the U-PGx proposal PHC-24-2015 – Piloting personalised medicine in health and care systems has been favourably evaluated by the Commission in stage 2 evaluations. The project will have a funding volume of 14,9 million Euros and a duration of 60 months. The grant agreement is expected to be finalised within the next 3 months.
We want to thank all U-PGx consortium members and advisors for their help in turning the U-PGx vision into a reality and are looking forward to our future collaboration!